Fig. 1.
Fig. 1. CCG 1922 schema. / (i) Abbreviations: OP, oral mercaptopurine/prednisone; IP, intravenous mercaptopurine/prednisone; OD, oral mercaptopurine/dexamethasone; ID, intravenous mercaptopurine/dexamethasone; PRED, prednisone; VCR, vincristine; L-ASP, L-asparaginase; IT, intrathecal; MTX, methotrexate; DEX, dexamethasone; 6MP, mercaptopurine; IV, intravenous; DOX, doxorubicin; CPM, cyclophosphamide; 6TG, thioguanine; ARA-C, cytarabine. (ii) Patients with central nervous system leukemia at diagnosis received 2400 cGy cranial radiation and 600 cGy spinal radiation therapy; patients with testicular disease at diagnosis received 2400 cGy bilateral testicular radiation therapy. (iii) Cycles of maintenance therapy continued for 20 months (girls) or 32 months (boys) from the start of maintenance therapy. Boldface signifies differences in therapy.

CCG 1922 schema.

(i) Abbreviations: OP, oral mercaptopurine/prednisone; IP, intravenous mercaptopurine/prednisone; OD, oral mercaptopurine/dexamethasone; ID, intravenous mercaptopurine/dexamethasone; PRED, prednisone; VCR, vincristine; L-ASP, L-asparaginase; IT, intrathecal; MTX, methotrexate; DEX, dexamethasone; 6MP, mercaptopurine; IV, intravenous; DOX, doxorubicin; CPM, cyclophosphamide; 6TG, thioguanine; ARA-C, cytarabine. (ii) Patients with central nervous system leukemia at diagnosis received 2400 cGy cranial radiation and 600 cGy spinal radiation therapy; patients with testicular disease at diagnosis received 2400 cGy bilateral testicular radiation therapy. (iii) Cycles of maintenance therapy continued for 20 months (girls) or 32 months (boys) from the start of maintenance therapy. Boldface signifies differences in therapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal